Log in

LON:DNLDiurnal Group Share Price, Forecast & News

GBX 30.50
0.00 (0.00 %)
(As of 07/3/2020 10:48 AM ET)
Add
Compare
Today's Range
30
Now: GBX 30.50
31
50-Day Range
30
MA: GBX 34.13
39
52-Week Range
19
Now: GBX 30.50
47
Volume64,514 shs
Average Volume7,428 shs
Market Capitalization£37.10 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Diurnal Group plc operates as a specialty pharma company. The company develops hormone therapeutics for the treatment of chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism, and hypothyroidism. Its product pipeline includes Infacort for use in children suffering from adrenal insufficiency; and Chronocort, which completed Phase III clinical trials targeting congenital adrenal hyperplasia in adult patients, as well as adrenal insufficiency. The company's early stage pipeline products comprise Native Oral Testosterone, a replacement treatment for patients suffering from hypogonadism; siRNA, a short interfering RNA oligonucleotide therapy for patients suffering from adrenocorticotropin-dependent Cushing's syndrome; and T3 modified, a modified-release preparation of T3 (levothyroxine) hormone for patients suffering from hypothyroidism. Diurnal Group plc was incorporated in 2015 and is headquartered in Cardiff, the United Kingdom.
Read More
Diurnal Group logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.29 out of 5 stars


Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-29-20682069

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£2.01 million
Cash FlowGBX 4.69 per share
Book ValueGBX 8.60 per share

Profitability

Miscellaneous

Employees23
Market Cap£37.10 million
Next Earnings DateN/A
OptionableNot Optionable

Receive DNL News and Ratings via Email

Sign-up to receive the latest news and ratings for DNL and its competitors with MarketBeat's FREE daily newsletter.

Diurnal Group (LON:DNL) Frequently Asked Questions

How has Diurnal Group's stock been impacted by COVID-19 (Coronavirus)?

Diurnal Group's stock was trading at GBX 34 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, DNL stock has decreased by 10.3% and is now trading at GBX 30.50. View which stocks have been most impacted by Coronavirus.

How were Diurnal Group's earnings last quarter?

Diurnal Group PLC (LON:DNL) issued its earnings results on Tuesday, February, 11th. The company reported ($4.70) EPS for the quarter. View Diurnal Group's earnings history.

Has Diurnal Group been receiving favorable news coverage?

News headlines about DNL stock have been trending very negative on Friday, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Diurnal Group earned a coverage optimism score of -3.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the next few days. View the latest news about Diurnal Group.

Who are some of Diurnal Group's key competitors?

What other stocks do shareholders of Diurnal Group own?

Who are Diurnal Group's key executives?

Diurnal Group's management team includes the following people:
  • Dr. Martin Whitaker B.Sc., BSc, Ph.D., CEO & Exec. Director
  • Mr. Richard Edward Bungay BSc, ACA, CFO,Director & Company Sec. (Age 50)
  • Prof. Richard Ross, Chief Scientific Officer & Exec. Director
  • Mr. Michael Withe, Commercial Director
  • Mr. John Porter, Medical Director

What is Diurnal Group's stock symbol?

Diurnal Group trades on the London Stock Exchange (LON) under the ticker symbol "DNL."

How do I buy shares of Diurnal Group?

Shares of DNL and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Diurnal Group's stock price today?

One share of DNL stock can currently be purchased for approximately GBX 30.50.

How big of a company is Diurnal Group?

Diurnal Group has a market capitalization of £37.10 million and generates £2.01 million in revenue each year. Diurnal Group employs 23 workers across the globe.

What is Diurnal Group's official website?

The official website for Diurnal Group is www.diurnal.co.uk.

How can I contact Diurnal Group?

Diurnal Group's mailing address is Heath Park, CARDIFF, CF14 4UJ, United Kingdom. The company can be reached via phone at +44-29-20682069.

This page was last updated on 7/3/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.